Solifenacin ( DrugBank: Solifenacin )

3 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	3
13	Multiple sclerosis/Neuromyelitis optica	1
53	Sjogren syndrome	1

6. Parkinson disease

Clinical trials : 2,298 / Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03149809 (ClinicalTrials.gov)	March 1, 2018	9/5/2017	Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease	Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease	Overactive Bladder;Parkinson Disease	Drug: solifenacin;Behavioral: Pelvic floor muscle exercise-based behavioral therapy	VA Office of Research and Development	NULL	Recruiting	N/A	N/A	All	90	Phase 3	United States
2	NCT01018264 (ClinicalTrials.gov)	January 2010	19/11/2009	Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease	URGE-PD: A Multi-site, Double-blind, Randomized, Placebo Controlled Trial of Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease	Overactive Bladder in Parkinson's Disease	Drug: solifenacin succinate (VESIcare);Drug: placebo	University of South Florida	NULL	Completed	40 Years	80 Years	All	23	Phase 4	United States
3	NCT00584090 (ClinicalTrials.gov)	November 2007	21/12/2007	Solifenacin Succinate (VESIcare) for the Treatment of Urinary Incontinence in Parkinson's Disease		Urinary Incontinence;Parkinson's Disease	Drug: Solifenacin Succinate (VESIcare);Drug: Placebo	University of South Florida	NULL	Withdrawn	30 Years	80 Years	Both	0	Phase 4	United States

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00629642 (ClinicalTrials.gov)	March 14, 2008	26/2/2008	Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis	A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity	Multiple Sclerosis;Neurogenic Bladder;Spinal Cord Diseases	Drug: Solifenacin Succinate;Drug: Oxybutynin Hydrochloride;Drug: Placebo	Astellas Pharma Inc	NULL	Completed	18 Years	65 Years	All	249	Phase 4	Australia;Belgium;Czechia;France;Germany;Hungary;Italy;Netherlands;Russian Federation;Spain;United Kingdom;Czech Republic;Portugal

Clinical trials : 283 / Drugs : 320 - (DrugBank : 101) / Drug target genes : 56 - Drug target pathways : 181

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04909255 (ClinicalTrials.gov)	March 23, 2021	21/4/2021	Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder	The Therapeutic Effect of Beta-3 Agonist and Anti-muscarinic Agent on Overactive Bladder Among Sjogren's Syndrome Patient	Sjogren's Syndrome;Overactive Bladder Syndrome	Drug: mirabegron;Drug: oxybutynin, tolterodine, solifenacin	China Medical University Hospital	NULL	Recruiting	20 Years	N/A	All	50	Phase 4	Taiwan